Mohammadreza Shafiei, Sayed-Hamidreza Mozhgani
Human T lymphotropic virus-associated myelopathy/tropical spastic paraparesis (HTLV/TSP), also known as HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP), and multiple sclerosis (MS) are chronic debilitating diseases of the central nervous system; although the etiology of which is different, similarities have been observed between these two demyelinating diseases, especially in clinical manifestation and immunopathogenesis. Exorbitant response of the immune system to the virus and neurons in CNS is the causative agent of HAM/TSP and MS, respectively...
March 22, 2023: Molecular Neurobiology
Rehab Sabry Helal, Saket Arya, Rami Abu Sbeit, Maha Elshafei
MS (Multiple sclerosis) associated uveitis used to have limited phenotypes. Bilateral exudative retinal detachment has never been recognized as a pattern of MS-associated uveitis. We are reporting a patient with multiple sclerosis who presented initially with the usual pattern of intermediate uveitis and later developed bilateral exudative retinal detachment.
March 22, 2023: Journal of Ophthalmic Inflammation and Infection
Laura Dumitrescu, Athanasios Papathanasiou, Catalina Coclitu, Afagh Garjani, Nikos Evangelou, Cris S Constantinescu, Bogdan Ovidiu Popescu, Radu Tanasescu
INTRODUCTION: Multiple sclerosis (MS) is an immune-mediated disorder of the CNS manifested by recurrent attacks of neurological symptoms (related to focal inflammation) and gradual disability accrual (related to progressive neurodegeneration and neuroinflammation). Sphingosine-1-phosphate-receptor (S1PR) modulators are a class of oral disease-modifying therapies (DMTs) for relapsing MS. The first S1PR modulator developed and approved for MS was fingolimod, followed by siponimod, ozanimod, and ponesimod...
March 22, 2023: Expert Opinion on Pharmacotherapy
Sebastiano Arena, Clara Grazia Chisari, Simona Toscano, Sebastiano Bucello, Luigi Maria Grimaldi, Paolo Ragonese, Sabrina Realmuto, Salvatore Cottone, Davide Maimone, Chiara Finocchiaro, Paola Reitano, Francesco Patti
BACKGROUND: cladribine tablets is a highly effective option for the treatment of relapsing-remitting multiple sclerosis (RRMS). OBJECTIVE: to evaluate the effectiveness of cladribine in a real-world setting. METHODS: this prospective real-world study consecutively screened all RRMS patients from seven different MS centers in Sicily (Italy), who completed the 2-year treatment course of cladribine tablets in the period between 11th March 2019 and 31st October 2021...
March 22, 2023: Current Neuropharmacology
T I Yakushina, D M Yakushin, I O Shtang
The appearance of new foci on MRI, the increase in neurological deficits, including the appearance of cognitive disorders and disturbances in the level of consciousness in patients with multiple sclerosis during the «washing period» when transferring from natalizumab (NZ) to another drug, may be due to both progressive multifocal leukoencephalopathy (PML) and exacerbation of the disease in the absence of therapy. Discontinuation of NS is fraught not only with a resumption, but with an increase in disease activity, the development of an immune reconstitution inflammatory syndrome (IRIS) due to the opening of the blood-brain barrier...
2023: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
Hüseyin Gökhan Yavaş, Ergin Sağtaş
BACKGROUND: Leukoaraiosis produces white matter lesions (WML) similar to multiple sclerosis (MS) on brain magnetic resonance imaging (MRI), and the distinction between these two conditions is difficult radiologically. This study aimed to investigate the role of the central vein sign (CVS) in susceptibility-weighted imaging (SWI) sequence in distinguishing MS lesions from leukoaraiosis lesions in Turkish population. METHODS: In this prospective study, axial SWI and sagittal three-dimensional fluid-attenuated inversion recovery (3DFLAIR) were obtained in 374 consecutive patients...
December 2022: Turkish Journal of Medical Sciences
Meryem Aslı Tuncer, Murat Kürtüncü, Murat Terzi, Uğur Uygunoğlu, Cansu Göncüoğlu, Ayşe Nur Yüceyar, Özgül Ekmekçi, Recai Türkoğlu, Aysun Soysal, Mesrure Köseoğlu, Cavit Boz, Yeşim Beckmann, Ömer Faruk Turan, Duruhan Meltem Demirkıran, Firdevs Gülşen Akman, Burcu Altunrende, İlknur Aydın Cantürk, Erkingül Birday, Abdulcemal Özcan, Özden Kamişli, Nazire Pinar Acar Özen, Rabia Gökçen Gözübatik Çelik, Fatma Belgin Balcı, Hüsnü Efendi, Cansu Sarıkaya, Aylin Akçalı, Münire Kılınç Toprak, Sibel Canbaz Kabay, Ferah Kızılay, Mustafa Serhan Sevim, Gülcan Baran Gazaloğlu, Caner Feyzi Demir, Ferhat Balgetir, Nefati Kıylıoğlu, Hande Sarıahmetoğlu, Çağcan Ölmez, Kamil Mavi, Süha Yüksel, Nihal Işık, Sabahattin Saip, Rana Karabudak, Aksel Siva, Mefküre Eraksoy
BACKGROUND: During multiple sclerosis (MS) treatment different modes of action such as lateral (interferon beta to glatiramer acetate or glatiramer acetate to interferon beta) or vertical (interferon beta/glatiramer acetate to fingolimod) drug switch can be performed. This study aims to investigate the clinical effectiveness of switching from the first-line injectable disease modifying treatments (iDMTs) to fingolimod (FNG) compared to switching between first-line iDMTs. METHODS: This is a multicenter, observational and retrospective study of patients with relapsing-remitting MS who had lateral and vertical switch...
February 2023: Turkish Journal of Medical Sciences
Benjamin V Ineichen, Carmen Cananau, Michael Platt N, Russell Ouellette, Thomas Moridi, Katrin B M Frauenknecht, Serhat V Okar, Zsolt Kulcsar, Ingrid Kockum, Fredrik Piehl, Daniel S Reich, Tobias Granberg
Virchow-Robin spaces (VRS) have been associated with neurodegeneration and neuroinflammation. However, it remains uncertain to what degree non-dilated or dilated VRS reflect specific features of neuroinflammatory pathology. Thus, we aimed at investigating the clinical relevance of VRS as imaging biomarker in multiple sclerosis (MS) and to correlate VRS to their histopathologic signature. In a cohort study comprising 205 MS patients (including a validation cohort) and 30 control subjects, we assessed the association of non-dilated and dilated VRS to clinical and magnetic resonance imaging (MRI) out-comes...
February 27, 2023: bioRxiv
Marius Marc-Daniel Mader, Alan Napole, Danwei Wu, Yohei Shibuya, Alexa Scavetti, Aulden Foltz, Micaiah Atkins, Oliver Hahn, Yongjin Yoo, Ron Danziger, Christina Tan, Tony Wyss-Coray, Lawrence Steinman, Marius Wernig
Multiple sclerosis (MS) is an autoimmune disease associated with inflammatory demyelination in the central nervous system (CNS). Autologous hematopoietic cell transplantation (HCT) is under investigation as a promising therapy for treatment-refractory MS. Here we identify a reactive myeloid state in chronic experimental autoimmune encephalitis (EAE) mice and MS patients that is surprisingly associated with neuroprotection and immune suppression. HCT in EAE mice leads to an enhancement of this myeloid state, as well as clinical improvement, reduction of demyelinated lesions, suppression of cytotoxic T cells, and amelioration of reactive astrogliosis reflected in reduced expression of EAE- associated gene signatures in oligodendrocytes and astrocytes...
March 12, 2023: bioRxiv
Susan L Lindsay, George A McCanney, Jiangshan Zhan, Miriam Scheld, Rebecca Sherrard Smith, Carl S Goodyear, Edwin A Yates, Markus Kipp, Jeremy E Turnbull, Susan C Barnett
There is an urgent need for therapies that target the multicellular pathology of central nervous system (CNS) disease. Modified, nonanticoagulant heparins mimic the heparan sulfate glycan family and are known regulators of multiple cellular processes. In vitro studies have demonstrated that low sulfated modified heparin mimetics (LS-mHeps) drive repair after CNS demyelination. Herein, we test LS-mHep7 (an in vitro lead compound) in experimental autoimmune encephalomyelitis (EAE) and cuprizone-induced demyelination...
March 21, 2023: Glia
A Gil-Sanchez, M Canudes, P Valcheva, L Nogueras, C González-Mingot, J V Hervás, S Peralta, M J Solana, L Brieva
INTRODUCTION: Vortioxetine is a multimodal antidepressant drug that has been reported to have a positive impact on cognition, social function, and fatigue. Nevertheless, it has not been widely studied. Our objective was to explore the effects of vortioxetine on these and other parameters in patients with multiple sclerosis (MS) and depression. PATIENTS AND METHODOLOGY: This observational case series study included patients with MS and depression who received treatment with vortioxetine for at least 6 months...
March 21, 2023: CNS & Neurological Disorders Drug Targets
Simone Mader, Samantha Ho, Hoi Kiu Wong, Selia Baier, Stephan Winklmeier, Carolina Riemer, Heike Rübsamen, Iris Marti Fernandez, Ramona Gerhards, Cuilian Du, Omar Chuquisana, Jan D Lünemann, Anja Lux, Falk Nimmerjahn, Monika Bradl, Naoto Kawakami, Edgar Meinl
Autoantibodies against myelin oligodendrocyte glycoprotein (MOG) have recently been established to define a new disease entity, MOG-antibody-associated disease (MOGAD), which is clinically overlapping with multiple sclerosis. MOG-specific antibodies (Abs) from patients are pathogenic, but the precise effector mechanisms are currently still unknown and no therapy is approved for MOGAD. Here, we determined the contributions of complement and Fc-receptor (FcR)-mediated effects in the pathogenicity of MOG-Abs. Starting from a recombinant anti-MOG (mAb) with human IgG1 Fc, we established MOG-specific mutant mAbs with differential FcR and C1q binding...
March 28, 2023: Proceedings of the National Academy of Sciences of the United States of America
F H Jacques, B E Apedaile, I Danis, V Sikati-Foko, M Lecompte, J Fortin
PURPOSE: Multiple sclerosis (MS) is a clinically heterogeneous disease. Biomarkers that can assess pathological processes that are unseen with conventional imaging remain an unmet need in MS disease management. Motor evoked potentials (MEPs) could be such a biomarker. To determine and follow longitudinal MEP reliability and correlations with clinical measures in MS patients. METHODS: This is a single-center study in alemtuzumab-treated MS patients to evaluate temporal reliability of MEPs, identify MEP minimum detectible differences, and explore correlations with existing clinical scales...
March 21, 2023: Journal of Clinical Neurophysiology: Official Publication of the American Electroencephalographic Society
Jan Moritz Fischer, Farid-Ihab Kandil, Matthias Karst, Laura Sophie Zager, Michael Jeitler, Felix Kugler, Franziska Fitzner, Andreas Michalsen, Christian S Kessler
BACKGROUND: Medical cannabinoids are controversial. Their use is comparatively rare, but it is rising. Since 2017, cannabinoids can be prescribed in Germany for a broader range of indications. Patient surveys on these drugs are hampered by the stigmatization of cannabinoids and their (still) low prevalence in medical contexts. Against this background, patients' willingness to provide information is limited. Moreover, it is logistically challenging to reach them with a survey. A thorough knowledge of currently ongoing therapies and their effects and side effects, however, is important for a more appropriate and effective use of cannabinoids in the future...
March 21, 2023: JMIR Research Protocols
Mariano Marrodan, Maria Agustina Piedrabuena, Maria Ines Gaitan, Marcela P Fiol, Maria Celica Ysrraelit, Edgar Carnero Conttenti, Pablo Adrian Lopez, Veronica Peuchot, Jorge Correale
BACKGROUND: Information on performance of multiple sclerosis (MS) diagnostic criteria is scarce for populations from Latin America, Asia, or the Caribbean. OBJECTIVE: To assess performance of revised 2017 McDonald criteria as well as evaluate genetic ancestry in a group of MS patients from Argentina experiencing a debut demyelinating event. METHODS: Demographic and clinical characteristics, cerebrospinal fluid (CSF), and magnetic resonance imaging (MRI) findings and new T2 lesions were recorded at baseline and during relapses...
March 21, 2023: Multiple Sclerosis: Clinical and Laboratory Research
Parham Pooladgar, Mehdi Sakhabakhsh, Arsia Taghva, Saeed Soleiman-Meigooni
Donepezil hydrochloride is an acetylcholine esterase inhibitor studied and approved to treat Alzheimer's disease (AD). However, this drug can have positive therapeutic potential in treating different conditions, including various neurodegenerative disorders such as other types of dementia, multiple sclerosis, Parkinson's disease, psychiatric and mood disorders, and even infectious diseases. Hence, this study reviewed the therapeutic potential of this drug in treating Alzheimer's and other diseases by reviewing the articles from databases including Web of Science, Scopus, PubMed, Cochrane, and Science Direct...
December 2022: Iranian Journal of Pharmaceutical Research: IJPR
Cristina Soria, Lola Prieto, Esther Lázaro, Amalia Ubeda
PURPOSE: Adherence to disease-modifying therapies (DMTs) in multiple sclerosis (MS) is a complex and multidimensional phenomenon. Identifying the predictors of therapeutic adherence in MS will guide the design of interventions to improve health outcomes. Our aim was to assess the degree of adherence to pharmacological treatments, assess the relationship between patient-related factors and pharmacological adherence and to identify predictors of adherence to pharmacological treatments in patients with MS in Spain...
2023: Patient Preference and Adherence
Justin Raman, Annie Jin, Jennifer J Parker, Conor M Vickers, Daniela M Proca, Sylvia Hsu, Jason B Lee
No abstract text is available yet for this article.
April 2023: JAAD Case Reports
Llucia Coll, Deborah Pareto, Pere Carbonell-Mirabent, Álvaro Cobo-Calvo, Georgina Arrambide, Ángela Vidal-Jordana, Manuel Comabella, Joaquín Castilló, Breogán Rodríguez-Acevedo, Ana Zabalza, Ingrid Galán, Luciana Midaglia, Carlos Nos, Annalaura Salerno, Cristina Auger, Manel Alberich, Jordi Río, Jaume Sastre-Garriga, Arnau Oliver, Xavier Montalban, Àlex Rovira, Mar Tintoré, Xavier Lladó, Carmen Tur
The application of convolutional neural networks (CNNs) to MRI data has emerged as a promising approach to achieving unprecedented levels of accuracy when predicting the course of neurological conditions, including multiple sclerosis, by means of extracting image features not detectable through conventional methods. Additionally, the study of CNN-derived attention maps, which indicate the most relevant anatomical features for CNN-based decisions, has the potential to uncover key disease mechanisms leading to disability accumulation...
March 15, 2023: NeuroImage: Clinical
Mathias Falck Schmidt, Gorm Pihl-Jensen, Marie Elise Wistrup Torm, Moschoula Passali, Michael Larsen, Jette Lautrup Frederiksen
BACKGROUND: Hyperreflective granular elements with a transient presence in the retina can be detected non-invasively by optical coherence tomography (OCT). Such foci or dots may represent aggregates of activated microglia. However, in multiple sclerosis an increased number of hyperreflective foci has so far not been demonstrated in the intrinsically hyporeflective and avascular outer nuclear layer of the retina where there are no fixed elements in healthy eyes. Therefore, the present study intended to investigate the presence of hyperreflective foci in the outer nuclear layer in patients with relapsing- remitting multiple sclerosis (RRMS) by using a high-resolution OCT scanning protocol...
March 12, 2023: Multiple Sclerosis and related Disorders
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.